Senior Research Scientist – DMPK
Elanco
Summary
As a Senior Research Scientist – DMPK, you will serve as a subject matter expert in drug metabolism and pharmacokinetics for discovery and pre-clinical research projects. In this role, you will be responsible for designing and implementing DMPK and PK/PD strategies that guide compound optimization, de-risking and accelerating early R&D programs through candidate selection and progression into the development pipeline.
Job description
Your Responsibilities
- Serve as the PK/DMPK scientific lead across multidisciplinary discovery and pre-clinical research teams, establishing strategies to guide small and large molecule candidates toward nomination.
- Design, execute, and monitor in vitro DMPK/ADME and in vivo PK/PD profiling studies to evaluate target exposure, bioavailability, metabolism, and drug interaction risks.
- Integrate DMPK findings with pharmacology and toxicology data to build robust lead profiles, perform IVIVC or mechanistic modeling, and drive go/no-go progression decisions.
- Collaborate cross-functionally across global R&D and partner with external CROs and academic collaborators to access specialized technologies and advance early pipeline packages.
- Prepare and deliver clear scientific summaries, reports, and presentations on DMPK findings to enable evidence-based governance decisions.
What You Need to Succeed (minimum qualifications)
- Education: Advanced scientific degree (PhD, PharmD, DVM, or Master's/Bachelor's degree with equivalent level of experience) in Pharmacology, Chemistry, Veterinary/Medical Sciences, or related scientific discipline.
- Required Experience: A minimum of 4 years of experience in pharmaceutical industry or academia in discovery and pre-clinical DMPK research, with demonstrated experience in both small and large molecule drug development.
- Strong foundational expertise in early-phase DMPK/ADME characterization, PK/PD data interpretation, and proficiency in PK software tools (such as Phoenix WinNonlin, Monolix, or equivalent).
What will give you a competitive edge (preferred qualifications)
- Experience with mechanistic PK modeling and/or physiologically-based pharmacokinetic (PBPK) modeling.
- Strong chemistry background with understanding of compound structures, classes, and in vitro profiling.
- Familiarity with veterinary drug development and species-specific considerations in animal metabolism and pharmacokinetics.
- Demonstrated experience managing and collaborating with external contract research organizations (CROs) and academic partners.
- Proven track record of cross-functional collaboration and delivering clear scientific presentations to diverse technical and non-technical audiences.
Additional Information
- Travel: Up to 10% of domestic and international travel
- Location: Global Elanco Headquarters - Indianapolis, IN - Hybrid Work Environment
Requirements
- Advanced scientific degree (PhD, PharmD, DVM, or Master's/Bachelor's degree with equivalent level of experience) in Pharmacology, Chemistry, Veterinary/Medical Sciences, or related scientific discipline.
- A minimum of 4 years of experience in pharmaceutical industry or academia in discovery and pre-clinical DMPK research, with demonstrated experience in both small and large molecule drug development.
- Strong foundational expertise in early-phase DMPK/ADME characterization, PK/PD data interpretation, and proficiency in PK software tools (such as Phoenix WinNonlin, Monolix, or equivalent).
Benefits
- Relocation packages
- Two weeklong shutdowns
- 8-week parental leave
- 9 Employee Resource Groups
- Annual bonus offering
- Flexible work arrangements
- Up to 6% 401K matching
Company overview
Elanco Animal Health Incorporated is a global leader in the animal health pharmaceutical industry, dedicated to improving the health and well-being of both pets and farm animals worldwide. Founded in 1954 as a division of Eli Lilly and Company, Elanco became an independent public company in 2018 and has since grown to become the world's second-largest independent animal health company. With approximately 9,000 employees globally, the company operates with a clear purpose: 'making life better for animals, makes life better.' Elanco develops innovative medicines, vaccines, and health solutions that empower veterinarians, farmers, and pet owners to advance animal care. The company maintains a balanced portfolio between pet health and farm animal products, offering over 200 brands that address critical health challenges ranging from companion animal diseases to livestock productivity. Headquartered in Indianapolis, Indiana, Elanco is publicly traded on the New York Stock Exchange (NYSE: ELAN) and continues to drive innovation in animal health through strategic acquisitions and dedicated research and development efforts.